Symphogen

Symphogen was founded in 2000 by Kirsten Drejer, a visionary in the field of biotechnology. The company, based in Ballerup, Denmark, set out with a mission to develop innovative recombinant antibody therapies aimed at treating cancer and other serious diseases. Symphogen's approach was unique, focusing on creating mixtures of monoclonal antibodies to enhance treatment efficacy and patient outcomes.

Over the years, Symphogen made significant strides in the biopharmaceutical industry, advancing its pipeline of antibody therapies through rigorous research and development. The company's dedication to innovation and patient care positioned it as a leader in the field of oncology-focused antibody treatments.

A pivotal moment in Symphogen's journey came in June 2020, when it became part of the Servier Group, a global pharmaceutical company. This acquisition was a strategic move to bolster Servier's oncology research and development capabilities, aligning with their commitment to improving patient health worldwide. The integration into Servier provided Symphogen with additional resources and support to further its mission of developing cutting-edge therapies.

Today, Symphogen continues to operate as a key player within the Servier Group, driving forward its research in antibody therapies. The company's story is one of innovation, resilience, and a steadfast commitment to transforming the landscape of cancer treatment through scientific excellence.